In patients with metastatic melanoma, treatments based on high doses of pro-inflammatory cytokines, such as IL-2, IL-12 and IFN⍺, decrease the disease burden, but display modest anti-tumor activity [89–91]. Here, IL2 is linked to neoplasm.